Dr Anita Asgar, Institut de Cardiologie de Montreal, commented,‘‘The challenges we face as clinicians is the need to preserve coronary access, but these are also patients who are also reasonably active, and we need to give them a good haemodynamic result, we need to really improve their symptoms so they can have a good quality of life”. Dr Asgar, who performed the procedures, stated,“As a clinician, it’s a great opportunity to have access to a technology that may help us with what is probably going to be a tsunami of valve-in-valve procedures that we are going to have to do”."These patients are in a challenging situation and are in need of a better option than what is commercially available. DurAVR™ delivered an outstanding result with meaningful patient benefits".
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)